Literature DB >> 20421581

Antibodies in patients with neuropsychiatric systemic lupus erythematosus.

A Kimura1, Y Kanoh, T Sakurai, A Koumura, M Yamada, Y Hayashi, Y Tanaka, I Hozumi, M Takemura, M Seishima, T Inuzuka.   

Abstract

OBJECTIVE: To investigate a target for antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE).
BACKGROUND: Pathogenesis of NPSLE may be related to autoantibody-mediated neural dysfunction, vasculopathy, and coagulopathy. However, very few autoantibodies are sensitive and specific to NPSLE because the neuropsychiatric syndromes associated with SLE are diverse in cause and presentation.
METHODS: We identified antibodies against brain antigens in the sera of 7 patients with NPSLE and 12 healthy controls by 2-dimensional electrophoresis, followed by Western blotting and liquid chromatography-tandem mass spectrometry (LC-MS/MS), using rat brain proteins as the antigen source.
RESULTS: Six antibodies were detected in patients with NPSLE. One of these 6 antibodies was found in antibodies against Rab guanosine diphosphate dissociation inhibitor alpha (alphaGDI) (which is specifically abundant in neurons and regulates synaptic vesicle exocytosis) in patients with NPSLE with psychosis. We tested more samples by 1-dimensional immunoblotting of human recombinant alphaGDI. Positivity of the anti-alphaGDI antibody was significantly higher in patients with NPSLE with psychosis (80%, 4 of 5) than in patients with NPSLE without psychosis (0%, 0 of 13), patients with systemic lupus erythematosus without neuropsychiatric symptoms (5.3%, 1 of 19), patients with multiple sclerosis (0%, 0 of 12), patients with infectious meningoencephalitis (0%, 0 of 13), patients with polyneuropathy (0%, 0 of 10), patients with psychotic syndromes (0%, 0 of 10), and healthy controls (0%, 0 of 12).
CONCLUSIONS: We propose that the anti-Rab guanosine diphosphate dissociation inhibitor alpha antibody is a candidate for further exploration as diagnostic marker of psychosis associated with neuropsychiatric systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421581     DOI: 10.1212/WNL.0b013e3181dad590

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Neuropsychiatric manifestations and associated autoantibodies in systemic lupus erythematosus patients from Western India.

Authors:  Vandana Pradhan; Manisha Patwardhan; Anjali Rajadhyaksha; Nivedita Dhawale; Kanjaksha Ghosh
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

2.  Anti-GAPDH Autoantibody Is Associated with Increased Disease Activity and Intracranial Pressure in Systemic Lupus Erythematosus.

Authors:  Jingjing Sun; Xue Li; Haotian Zhou; Xiaoyun Liu; Jingjing Jia; Qizhi Xie; Sijia Peng; Xiaolin Sun; Qingwen Wang; Li Yi
Journal:  J Immunol Res       Date:  2019-03-31       Impact factor: 4.818

Review 3.  Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus.

Authors:  Erik A Korte; Patrick M Gaffney; David W Powell
Journal:  Arthritis Res Ther       Date:  2012-02-20       Impact factor: 5.156

4.  An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies.

Authors:  Virginie Dutoit-Lefèvre; Sylvain Dubucquoi; David Launay; Vincent Sobanski; Patricia Dussart; Philippe Chafey; Cédric Broussard; Sophie Duban-Deweer; Patrick Vermersch; Lionel Prin; Didier Lefranc
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

5.  Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis.

Authors:  A Zandian; L Wingård; H Nilsson; E Sjöstedt; D X Johansson; D Just; C Hellström; M Uhlén; J M Schwenk; A Häggmark-Månberg; O Norbeck; B Owe-Larsson; P Nilsson; M A A Persson
Journal:  Transl Psychiatry       Date:  2017-07-25       Impact factor: 6.222

Review 6.  Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review.

Authors:  Orthodoxia Nicolaou; Andreas Kousios; Andreas Hadjisavvas; Bernard Lauwerys; Kleitos Sokratous; Kyriacos Kyriacou
Journal:  J Cell Mol Med       Date:  2016-11-23       Impact factor: 5.310

7.  Anti-PDHA1 antibody is detected in a subset of patients with schizophrenia.

Authors:  Yukako Nakagami; Genichi Sugihara; Noriyuki Nakashima; Masaaki Hazama; Shuraku Son; Shuhe Ma; Riki Matsumoto; Toshiya Murai; Akio Ikeda; Kosaku Murakami
Journal:  Sci Rep       Date:  2020-05-13       Impact factor: 4.379

8.  Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.

Authors:  Misato Jono; Yuhei Kinehara; Yoshihiko Utsu; Yoshiro Tamura; Masahiro Koseto; Teruaki Murakami; Akifumi Uota; Ryusuke Ninomiya; Satoshi Komo; Satoru Sumitani; Bunzo Sato; Soji Kasayama; Isao Tachibana
Journal:  Intern Med       Date:  2019-10-31       Impact factor: 1.271

Review 9.  Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

Authors:  Elias Manca
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-11       Impact factor: 10.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.